Figure 6
![Figure 6](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2F1743-7075-5-23/MediaObjects/12986_2008_Article_147_Fig6_HTML.jpg)
Antagonists of GPR142 are candidate future obesity drugs. Anti-sense knockdown of G-protein coupled receptor gene products the loss of function previously determined to cause decrease in fat content [12]. Incubation with the stable beta-adrenergic agonist isoproterenol is shown as a positive control causing increased lipolysis for comparison.